A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.
about
Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?A review of human drug self-administration procedures.The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitabilityDiversion and Illicit Sale of Extended Release Tapentadol in the United StatesA practical and ethical solution to the opioid scheduling conundrum.How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction.Where do we stand in the field of anti-abuse drug discovery?The role of abuse-deterrent formulations in countering opioid misuse and abuse.Opioid abuse-deterrent strategies: role of clinicians in acute pain management.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Designing a tool allowing for a standardized assessment of resistance to drug diversion.Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.Tampering of opioid analgesics: a serious challenge for public health?The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.
P2860
Q26740394-C4D877EC-9F12-4E80-AE5E-A9286CC206D8Q33841805-A55A8508-D7B4-43B7-9EB7-4BAF03204D07Q35209803-FC1B1FCF-8629-4B31-8386-0BE7D5A752CAQ37154667-6C5B0242-63BC-4F62-8D8E-EE15BFB24BCBQ37390980-C0B83B2A-BD9B-4E17-98A4-86B283A7418DQ37459006-507C11C5-03BC-4D25-9E40-17BF81D72670Q38243888-1D952AE7-8D60-406B-B57D-9232842AC556Q38643510-AB011DC0-0AA9-4848-833F-587234E43008Q38657470-9DC1BBF8-1067-4828-8793-F8B6772EDCF1Q38683620-9411E139-B87D-4D33-95D7-B52D568B9441Q38707436-59B45FD5-E2AF-4B55-AD84-6DF38E7213ACQ43317466-6A13172B-433A-484F-B304-D13A6211C9E8Q44329825-80095615-937C-4439-875A-579C53DAF317Q44337858-6D703AB1-20F5-4C46-9D2D-C103693DA705Q44345212-F9058836-2976-4F33-A9F2-3EDBBD5B9A9CQ52603231-36C3359D-B962-4B88-A0AD-01FA5C2DD7B0
P2860
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A comparison among tapentadol ...... n prescription opioid abusers.
@en
type
label
A comparison among tapentadol ...... n prescription opioid abusers.
@en
prefLabel
A comparison among tapentadol ...... n prescription opioid abusers.
@en
P2093
P2860
P356
P1433
P1476
A comparison among tapentadol ...... n prescription opioid abusers.
@en
P2093
Douglas Y Shapiro
Jeanne M Manubay
Jermaine D Jones
Judy B Ashworth
Sandra D Comer
Suzanne K Vosburg
P2860
P304
P356
10.1111/ADD.12114
P407
P577
2013-03-13T00:00:00Z